Terns Pharmaceuticals (TERN) Competitors $7.30 +0.17 (+2.38%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$7.46 +0.16 (+2.25%) As of 09/16/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. CGON, ALVO, CPRX, TARS, IDYA, OCUL, MLYS, IBRX, DNLI, and IRONShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Denali Therapeutics Disc Medicine CG Oncology (NASDAQ:CGON) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends. Is CGON or TERN more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -19.37% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-15,945.17% -19.37% -18.72% Terns Pharmaceuticals N/A -27.35%-26.18% Does the media refer more to CGON or TERN? In the previous week, CG Oncology had 11 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 15 mentions for CG Oncology and 4 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.19 beat CG Oncology's score of 0.88 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CGON or TERN? CG Oncology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Do analysts rate CGON or TERN? CG Oncology currently has a consensus target price of $53.91, indicating a potential upside of 50.75%. Terns Pharmaceuticals has a consensus target price of $15.61, indicating a potential upside of 113.84%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do institutionals and insiders have more ownership in CGON or TERN? 26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation and earnings, CGON or TERN? CG Oncology has higher revenue and earnings than Terns Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$1.14M2,391.84-$88.04M-$1.77-20.20Terns PharmaceuticalsN/AN/A-$88.85M-$1.04-7.02 SummaryCG Oncology beats Terns Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$623.95M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-7.0221.1675.8626.51Price / SalesN/A446.35528.72123.58Price / CashN/A45.4037.1760.46Price / Book1.799.6212.796.29Net Income-$88.85M-$53.28M$3.28B$270.51M7 Day Performance-2.28%1.01%0.81%1.95%1 Month Performance3.55%4.58%4.60%6.33%1 Year Performance-24.20%8.35%70.39%25.62% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals3.9906 of 5 stars$7.30+2.4%$15.61+113.8%-22.4%$623.95MN/A-7.0240Positive NewsCGONCG Oncology2.4386 of 5 stars$33.69+1.9%$53.91+60.0%-3.4%$2.52B$1.14M-19.0361News CoverageAnalyst ForecastInsider TradeGap UpHigh Trading VolumeALVOAlvotech3.7274 of 5 stars$8.16-2.0%$14.00+71.6%-26.8%$2.51B$491.98M35.481,032Positive NewsShort Interest ↓CPRXCatalyst Pharmaceuticals4.9523 of 5 stars$20.08-1.0%$33.20+65.3%-1.8%$2.48B$491.73M12.1780Positive NewsTARSTarsus Pharmaceuticals2.4891 of 5 stars$56.89-1.3%$66.67+17.2%+58.7%$2.43B$182.95M-24.4250Positive NewsIDYAIDEAYA Biosciences3.9574 of 5 stars$23.39-13.9%$45.77+95.7%-32.9%$2.38B$7M-6.1780High Trading VolumeOCULOcular Therapeutix3.8933 of 5 stars$12.71-6.5%$17.20+35.3%+39.3%$2.37B$63.72M-9.93230Analyst ForecastMLYSMineralys Therapeutics2.9012 of 5 stars$35.93+3.2%$36.60+1.9%+222.6%$2.31BN/A-10.0928Insider TradeIBRXImmunityBio2.4986 of 5 stars$2.41+0.4%$10.75+346.1%-19.5%$2.27B$14.74M-5.02590DNLIDenali Therapeutics4.3593 of 5 stars$15.50+0.5%$33.50+116.1%-56.3%$2.26B$330.53M-5.54430Positive NewsIRONDisc Medicine3.2198 of 5 stars$61.91+1.9%$98.30+58.8%+26.6%$2.11BN/A-13.8530Positive NewsHigh Trading Volume Related Companies and Tools Related Companies CG Oncology Competitors Alvotech Competitors Catalyst Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors IDEAYA Biosciences Competitors Ocular Therapeutix Competitors Mineralys Therapeutics Competitors ImmunityBio Competitors Denali Therapeutics Competitors Disc Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TERN Stock Alerts